Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 9/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 9/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.37 |
| ▸ | APP | P05067 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | GBA1 | P04062 | 1/20 | 0.34 |
| ▸ | CLK4 | Q9HAZ1 | 7/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24240133 | 0.72 | RPS6KA5 (0.30) | — | |
| SCHEMBL28006645 | 0.70 | CLK4 (0.50) | CYP1A2CYP3A4CYP2C19CYP2D6SMN1; SMN2 | |
| SCHEMBL24375911 | 0.69 | CYP1A2 (0.41) | CYP1A2CYP3A4CYP2C19CYP2D6CYP2C9 | |
| SCHEMBL5913801 | 0.68 | — | — | |
| SCHEMBL28157940 | 0.65 | FLT3 (0.37) | CYP1A2 | |
| SCHEMBL8340318 | 0.65 | KDM4E (0.42) | CYP3A4KDM4ETP53HPGDSMN1; SMN2 | |
| SCHEMBL24142565 | 0.65 | CYP3A4 (0.40) | CYP3A4NPC1HPGDSMN1; SMN2ALDH1A1 | |
| SCHEMBL28245462 | 0.63 | CYP1A2 (0.33) | CYP1A2 | |
| SCHEMBL24254425 | 0.62 | CYP3A4 (0.38) | CYP1A2CYP3A4CYP2D6KDM4EHPGD | |
| SCHEMBL12651710 | 0.62 | CCR1 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060069110-A1 | Substituted heterocyclic compounds and methods of use | AMGEN INC. | 2006-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069110-A1 | Substituted heterocyclic compounds and methods of use | MAPT, MYLK2, IAPP | CYP1A2 1159/4885CYP3A4 1290/4885CYP2C19 2820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.